KRAS and lung carcinoma: Research has shown that knocking down CSNK2A1 in KRAS (G12C) mutant lung cancer cells reduced cell proliferation, inhibited Wnt/β-catenin signaling, and enhanced the anti-proliferative effects of MEK inhibitors on KRAS (G12C) mutant lung cancer cells (49).